High glucose metabolism due to GLUT1/ALDOB/G6PD axis expression promotes drug resistance in pancreatic cancer, and inhibition of the GLUT1/ALDOB/G6PD axis may serve as a target for drug resistance therapy [34]. The gene discussed is SLC2A1; the disease is pancreatic neoplasm.